Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of
Non-small Cell Lung Cancer with MET Alterations / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 684-691, 2023.
Article
in Zh
| WPRIM
| ID: wpr-1010075
Responsible library:
WPRO
ABSTRACT
Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is inevitable. Molecular mechanisms of resistance to MET-TKIs are completely unclear. The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to delay and prevent resistance.
.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
/
Epithelial-Mesenchymal Transition
/
ErbB Receptors
/
Lung Neoplasms
/
Mutation
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Lung Cancer
Year:
2023
Document type:
Article